Literature DB >> 9314969

Liver metastases from colorectal cancer: drug delivery with liposome-encapsulated doxorubicin.

O Cay1, J B Kruskal, I Nasser, P Thomas, M E Clouse.   

Abstract

PURPOSE: To evaluate the intratumoral distribution of liposome-encapsulated doxorubicin.
MATERIALS AND METHODS: Tumor-bearing livers of 24 mice were studied with in vivo fluorescence and electron microscopy after injection of liposomal doxorubicin in the hepatic artery, portal vein, or tail vein. Distribution and uptake of liposomes and doxorubicin in tumors were compared at 5, 30, and 60 minutes after injection. In vitro evaluation of uptake of doxorubicin in Kupffer cells and in human colorectal cancer cells incubated under normoxic and hypoxic conditions for 5, 30, and 60 minutes was performed with fluorescence microscopy.
RESULTS: Doxorubicin autofluorescence was seen in tumors 30 minutes after intraarterial and intraportal injection and was statistically significantly greater at 60 minutes (P < .001). Liposomes were observed in small tumors (diameter < 300 microns) and were trapped in Kupffer cells around larger, hypovascular tumors. Electron microscopy findings confirmed intracytoplasmic, perinuclear uptake of liposomes in tumor cells. In vitro, a higher proportion of doxorubicin was seen in cancer cells (92%) than in Kupffer cells (75%) after 60 minutes incubation.
CONCLUSION: Liposomal doxorubicin can be reliably delivered to liver metastases via the hepatic artery, eliminating need for tumor embolization. Further evaluation is warranted, and the drug may be useful for treating patients with unresectable liver metastases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314969     DOI: 10.1148/radiology.205.1.9314969

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

1.  Ileal carcinoid tumor with liver metastases and cardiac involvement treated with intraarterial liposomal doxorubicin and valve replacement.

Authors:  M González Cao; G Bastarrika; J García-Foncillas; J Aristu; A Chopitea; S Martín Algarra
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

Review 2.  Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials.

Authors:  Natalia Krasteva; Milena Georgieva
Journal:  Pharmaceutics       Date:  2022-06-07       Impact factor: 6.525

Review 3.  Targeted nanoparticles for colorectal cancer.

Authors:  Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos
Journal:  Nanomedicine (Lond)       Date:  2016-08-16       Impact factor: 5.307

4.  Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma.

Authors:  Pierluigi Pilati; Simone Mocellin; Carlo R Rossi; Romano Scalerta; Rita Alaggio; Luciano Giacomelli; Cristina Geroni; Donato Nitti; Mario Lise
Journal:  World J Surg       Date:  2003-05-13       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.